CA-MARY-KAY
24.2.2021 14:36:06 CET | Business Wire | Press release
Glamhive announced its fourth online conference to be held on February 27, 2021. The Glamhive Digital Winter Style and Beauty Summit will bring together top fashion and beauty leaders, from Kristen Bell's stylist to billion-dollar founder-turned female founder investor Cindy Eckert. The innovative leaders will discuss fashion, beauty, entrepreneurship, and more. Stephanie Sprangers and Nicole Chavez will co-host the event.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005275/en/
"I have loved being part of Glamhive's style & beauty summits, particularly during this challenging time. The summits have brought a sense of community, which is lacking in the world of creative talent, plus I have made some amazing connections with other artists along the way," said Nicole Chavez, celebrity stylist. Nicole is one of the most in-demand stylists today. Her clientele has ranged from A-List stars Kristen Bell, Rachel Bilson, Jessica Simpson, Ellie Bamber, Scarlett Johansson, Catherine Zeta-Jones, and many more. Her work has been featured in many publications, including W, InStyle, and Harper's Bazaar.
"Glamhive's vision is to give the benefits of working with a personal stylist available to everyone, everywhere, and our digital events are a wonderful extension of that. The silver lining of the past year is that it enabled us to pivot our style summits to digital, thereby making it possible for everyone, everywhere to meet and learn from the best in the business," said Stephanie Sprangers, Glamhive Founder and CEO. Sprangers is the Founder and Chief Executive Officer of Glamhive, the online personal styling service that brings expert personal stylists and makeup artists—recruited directly from Hollywood and Instagram—to everyone. Glamhive has developed proprietary software that allows stylists to take clients through a styling experience that is 100% online, allowing people to work with stylists anywhere in the world.
The all-day, ticketed event will feature over 60 speakers. Below is an overview of some of the topics that this all-star speaker line-up will cover.
TOPICS SNAPSHOT:
The day will consist of 22 segments across two-tracks. A snapshot:
- Red Carpet Style: Creating Iconic Style Moments
- 2021 Trends: Post-Pandemic Style
- Winning the Style Game: Vintage is Your Secret Weapon
- The Stylists Playbook: How to Get the Best Style of Your Life
- Beauty Boss Babe: An Interview with Jamie Kern Lima
- The Ultimate Guide to "Easy" Hair
- Let's Get Social: The Best Instagram and TikTok Beauty Trends
- The Astrology of Fashion: With Susan Miller
- More Than Meets the Eye: What Your Clothes Say About You
- The ROI of Style: How Dressing Well Pays Off
- How I Built This: Darn Good Advice from Women Who Made It to the Top
SPEAKERS:
Speakers include celebrity stylists, makeup artists, image-makers who work with the biggest names in Hollywood and beyond, including:
Angelina Jolie, Serena Williams, Mandy Moore, Sarah Jessica Parker, Kristen Bell, Khloe Kardashian, Robert Downey Jr., Keanu Reeves, Sharon Stone, Serena Williams, Miranda Lambert, Julianne Moore, and more.
CELEBRITY STYLISTS:
Nicole Chavez, Jill + Jordan, Jeanne Yang, Jennifer Rade, Tara Swennen, Janelle Miller, Lindsey Dupuis, Tiffany Gifford, Kesha McLoud, and Sonia Young.
CELEBRITY MAKEUP ARTISTS + HAIRSTYLISTS:
Tommy Buckett, Todd Harris, Diana Madison, Danny Moon, AJ Crimson, and Helen Reavey.
ENTREPRENEURS, DESIGNERS, AND BUSINESS LEADERS:
Claire Sulmers (Fashion Bomb Daily), Hillary Kerr (WhoWhatWear), Tara Rudes Dann (L'Agence), Steven Dann (Designer), Cindy Eckert (The Pink Ceiling Fund), Helen Ravey (Act+Acre), Cassandra Cadwell (Violet Grey), Michelle Waugh (Designer), Clarissa Egana (Port De Bras), Amy Rosoff Davis (Celebrity Trainer), Jamie Kern Lima (IT Cosmetics).
MODERATORS:
Brian Underwood (O Magazine), Brooke Jaffe (Penske Media), Pandora Amoratis (Daily Mail), Andrea Lavanthal (PEOPLE), Robin Nazzaro (O Magazine), Alexis Bennett (Vogue) and Kibwe Chase-Marshall (The Kelly Initiative).
Tickets to the conference are $149 for an all-day ticket. The Glamhive Digital Winter Style and Beauty Summit's presenting sponsor is Mary Kay Inc. and its Mary Kay Global Design Studio.
For more information, visit www.glamhive.com/upcoming .
About Glamhive
Glamhive was founded by entrepreneur Stephanie Sprangers in 2017 with the vision to democratize personal styling and the premise that the confidence that comes with glamour should not be exclusive to the rich and famous.
The online styling experience offers anyone with a WiFi connection access to stylists who will provide them with the support they need to be the best version of themselves. The Glamhive platform is a seamless end-to-end platform for stylists to help them grow their network and their business, 100% virtually.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 57 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005275/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom